Literature DB >> 8383031

Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.

S C Lafredo1, B D Foleno, K P Fu.   

Abstract

Twelve strains of Streptococcus pneumoniae were serially exposed to increasing concentrations of levofloxacin, temafloxacin, ciprofloxacin and norfloxacin for five passages. Wild-type and passaged strains were tested for susceptibility to quinolones, macrolide and penicillin G. The MIC90 data showed a 2-fold increase for levofloxacin but a 32-fold increase for ciprofloxacin, a 16-fold increase for temafloxacin and an 8-fold increase for norfloxacin. Among 16 ciprofloxacin-induced resistant strains, 14 were susceptible to levofloxacin. No cross-resistance to other antibiotics was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383031     DOI: 10.1159/000238971

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

Authors:  V Zeller; C Janoir; M D Kitzis; L Gutmann; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.

Authors:  M K Lacy; W Lu; X Xu; P R Tessier; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 6.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 7.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.